Localized Prostate Cancer
27
10
15
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 27 trials
100.0%
+13.5% vs benchmark
11%
3 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (27)
WATER IV Prostate Cancer
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE)
The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer
Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
Active Surveillance Exercise Clinical Trial
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.
Radical Hypofractionated Radiotherapy for Localized Prostate Cancer
Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer
Clinical Study of HIFU for Localized Prostate Cancer
PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer
Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer